Use of monoclonal antibodies in vivo as a therapeutic strategy for alloimmune or autoimmune reactivity: the Besançon experience

Immunol Rev. 1992 Oct:129:31-55. doi: 10.1111/j.1600-065x.1992.tb01418.x.
No abstract available

Publication types

  • Clinical Trial
  • Clinical Trial, Phase I
  • Clinical Trial, Phase II
  • Multicenter Study
  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Adult
  • Aged
  • Antibodies, Monoclonal / therapeutic use*
  • Arthritis, Rheumatoid / therapy
  • Autoimmune Diseases / therapy*
  • Bone Marrow Transplantation
  • Cytokines / immunology
  • Graft vs Host Disease / therapy*
  • Humans
  • Middle Aged
  • Multiple Sclerosis / therapy
  • Pilot Projects
  • Receptors, Interleukin-2 / immunology*
  • T-Lymphocytes / immunology*

Substances

  • Antibodies, Monoclonal
  • Cytokines
  • Receptors, Interleukin-2